Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in Relapsed or Refractory Hemangioendothelioma and Other ISSVA Group I or II Vascular Malformations and Neoplasms
KCT0011734Phase 2Not yet recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in arteriovenous malformation (AVM), venous malformation (VM), lymphangioma, port-wine stain, hemangioendothelioma, sponsored by Samyang Biopharmaceuticals Corporation. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
everolimus
03
Conditions
arteriovenous malformation (AVM)venous malformation (VM)lymphangiomaport-wine stainhemangioendothelioma
Beyond the preview
Go deeper on KCT0011734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011734.